Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Published 11/04/2024, 18:33
Updated 11/04/2024, 19:40
© Reuters.  Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.

Fastenal reported first-quarter FY24 sales growth of 1.9% Y/Y to $1.895 billion, missing the consensus of $1.914 billion. The company's first-quarter EPS was 52 cents, missing the consensus of 53 cents.

Fastenal shares dipped 6.7% to $69.73 on Thursday.

Here are some other stocks moving in today's mid-day session.

Gainers

  • Rallybio Corporation (NASDAQ: RLYB) shares climbed 89.6% to $3.09 after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT.
  • Rent the Runway, Inc. (NASDAQ: RENT) shares jumped 74.5% to $12.91 after the company reported mixed fourth-quarter financial results and issued guidance.
  • Eliem Therapeutics, Inc. (NASDAQ: ELYM) jumped 59.6% to $4.2650. The company announced that it entered into a definitive acquisition agreement to acquire Tenet and it also entered into a securities purchase agreement for a $120 million private placement.
  • Akanda Corp. (NASDAQ: AKAN) gained 36% to $0.1632. Akanda, last month, announced a plan to evaluate opportunities in Bitcoin, Blockchain and AI applications in the cannabis industry.
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN) rose 36.6% to $64.25 after Vertex entered into an agreement to acquire the company.
  • Candel Therapeutics, Inc. (NASDAQ: CADL) surged 29.6% to $6.61 after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer.
  • Enliven Therapeutics, Inc. (NASDAQ: ELVN) gained 26% to $24.97. Enliven Therapeutics announced proof of concept data from Phase 1 clinical trial of ELVN-001 in chronic myeloid leukemia.
  • Selina Hospitality PLC (NASDAQ: SLNA) rose 21.1% to $0.0923.
  • Globavend Holdings Limited (NASDAQ: GVH) climbed 16.8% to $1.68.
  • Janux Therapeutics, Inc. (NASDAQ: JANX) gained 16.8% to $52.15 following Wednesday reports suggesting the company is said to weigh a possible sale.
  • SciSparc Ltd. (NASDAQ: SPRC) shares rose 15.3% to $1.9357.
  • Gyre Therapeutics, Inc. (NASDAQ: GYRE) gained 14.6% to $15.91.
  • AnaptysBio, Inc. (NASDAQ: ANAB) climbed 11.4% to $24.72. Wells Fargo analyst Derek Archila initiated coverage on AnaptysBio with an Overweight rating and announced a price target of $56.
  • Verb Technology Company, Inc. (NASDAQ: VERB) gained 10.4% to $0.2010 after gaining 4% on Wednesday.
  • GigaCloud Technology Inc. (NASDAQ: GCT) rose 10.2% to $34.18.
  • Nurix Therapeutics, Inc. (NASDAQ: NRIX) gained 9.6% to $17.21. Baird analyst Joel Beatty maintained Nurix Therapeutics with an Outperform and raised the price target from $24 to $25.
  • StepStone Group LP (NASDAQ: STEP) rose 7.1% to $37.46 after JP Morgan upgraded the stock from Neutral to Overweight.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
Losers
  • Aptevo Therapeutics Inc. (NASDAQ: APVO) shares fell 58% to $1.01 after the company priced its $4.6 million public offering.
  • Enlivex Therapeutics Ltd. (NASDAQ: ENLV) fell 54.5% to $1.81. The company announced topline results of its Phase II trial evaluating Allocetra in sepsis.
  • AVITA Medical, Inc. (NASDAQ: RCEL) fell 28.6% to $10.31 after the company announced an update to its expected commercial revenue for the first quarter of 2024. BTIG downgraded the stock from Buy to Neutral.
  • Aesthetic Medical International Holdings Group Limited (NASDAQ: AIH) fell 19% to $0.3723.
  • Globe Life Inc. (NYSE: GL) fell 14.6% to $89.65.
  • The Lovesac Company (NASDAQ: LOVE) shares fell 14.3% to $20.00 after the company reported worse-than-expected fourth-quarter results and issued first-quarter guidance.
  • Globe Life Inc. (NYSE: GL) fell 13.7% to $90.56.
  • Meiwu Technology Company Limited (NASDAQ: WNW) shares declined 12.4% to $1.1601 after jumping around 32% on Wednesday.
  • Acorda Therapeutics, Inc. (NASDAQ: ACOR) fell 12% to $0.7660 after declining 14% on Wednesday. Acorda Therapeutics recently commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code.
  • CarMax, Inc. (NYSE: KMX) fell 11.7% to $70.02 after the company reported lower-than-expected fourth-quarter earnings.
  • VBI Vaccines Inc. (NASDAQ: VBIV) dipped 11.3% to $0.5641.
  • Nikola Corporation (NASDAQ: NKLA) fell 11.3% to $0.8680. On April 9, Wolfe Research analyst Scott Group initiated coverage on Nikola with a Peer Perform rating.
  • Marin Software Incorporated (NASDAQ: MRIN) declined 10.8% to $0.5798.
  • SolarBank Corporation (NASDAQ: SUUN) fell 9.3% to $5.29. SolarBank closed purchase of 3.15 MW solar project in New York from Storke Renewable.
  • Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 9.1% to $2.29.
  • 9F Inc. (NASDAQ: JFU) fell 8.8% to $2.7046.
  • iCoreConnect Inc. (NASDAQ: ICCT) shares fell 8.5% to $1.55 after jumping over 50% on Wednesday.
  • ClearOne, Inc. (NASDAQ: CLRO) declined 8.3% to $1.00. The company recently reported fourth-quarter financial results.
  • Nyxoah S.A. (NASDAQ: NYXH) fell 7.3% to $9.83
  • Acorda Therapeutics, Inc. (NASDAQ: ACOR) fell 6.2% to $0.8164.
  • Walker & Dunlop, Inc. (NYSE: WD) fell 5.3% to $87.71 after Wedbush downgraded the stock from Outperform to Neutral and lowered its price target from $130 to $95.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Now Read This: Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.